Life Science Analytics (LSA)Overview Our Products
Each report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, day’s sales outstanding, day’s outstanding inventory, cash and short-term investments per share and total common shares outstanding. Finally each report includes quarterly book value per share vs. share price. Much of the information contained in each report is included in both tabular and graphic formats.
Product Pipeline Reports
Competitor Reports
Deals & Alliances Reports
|
List of reports from Life Science Analytics (LSA)
|
Brainfarma Industria Quimica e Farmaceutica Ltda.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... development, and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as ...
|
more...
|
$350.00
|
|
Eli Lilly Asia, Inc-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...
|
more...
|
$350.00
|
|
Eli Lilly Italia S.p.A.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...
|
more...
|
$350.00
|
|
Lilly Netherlands BV-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the ...
|
more...
|
$350.00
|
|
Eli Lilly and Trade Co., Ltd-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... development, and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as ...
|
more...
|
$350.00
|
|
Horus Pharma-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...
|
more...
|
$350.00
|
|
Eli Lilly Norway A.S-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...
|
more...
|
$350.00
|
|
Eli Lilly Vostok SA-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...
|
more...
|
$350.00
|
|
Eli Lilly Inter-America Inc-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...
|
more...
|
$350.00
|
|
Boehringer Ingelheim (Canada) Ltd.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...
|
more...
|
$350.00
|
|
Boehringer Ingelheim Mexico, SA-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...
|
more...
|
$350.00
|
|
Roxane Laboratories, Inc.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the ...
|
more...
|
$350.00
|
|
MSD Australia-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...
|
more...
|
$350.00
|
|
Merck Sharp & Dohme, IDEA A.G. (MSD)-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... of development, and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well ...
|
more...
|
$350.00
|
|
Astellas Pharma Hong Kong Co., Ltd-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... development, and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as ...
|
more...
|
$350.00
|
|
Astellas Pharma Korea, Inc.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...
|
more...
|
$350.00
|
|
Astellas Pharma China Inc.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...
|
more...
|
$350.00
|
|
Tentan AG-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...
|
more...
|
$350.00
|
|
Macronova AB-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...
|
more...
|
$350.00
|
|
Borisov Plant of Medical Substances-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight ...
|
more...
|
$350.00
|
|
Unipharm, Inc.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...
|
more...
|
$350.00
|
|
Flordis-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted likelihood ...
|
more...
|
$350.00
|
|
SOFAR s.p.a.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...
|
more...
|
$350.00
|
|
Pabianickie Zaklady Farmaceutyczne Polfa S.A.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight ...
|
more...
|
$350.00
|
|
RKG Pharma Pvt. Ltd.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...
|
more...
|
$350.00
|

